Meeting
2019 Genitourinary Cancers Symposium
Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
Authors
Megan Ann McNamara
Duke University School of Medicine, Durham, NC
Megan Ann McNamara , Daniel J. George , Krishnan Ramaswamy , Stanislav Lechpammer , Jack Mardekian , Neil M. Schultz , Li Wang , Onur Baser , Ahong Huang , Stephen J. Freedland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 212)
DOI
10.1200/JCO.2019.37.7_suppl.212
Abstract #
212
Poster Bd #
J13
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Frailty and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
First Author: Ekamjit Singh Deol
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival in Black and non-Black patients with metastatic prostate cancer.
First Author: Nina Cheranda
Poster
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Daniel Joseph Khalaf